Olmesartán/Amlodipino Sandoz (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxomil and amlodipine, the active ingredient in Olmesartán/Amlodipino Sandoz, is an Angiotensin II receptor blocker / Calcium channel blocker combination presented as a tablet for oral use. It treats hypertension by lowering blood pressure in adult patients.

GNH USA supplies Olmesartán/Amlodipino Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan/Amlodipine acts on the renin‑angiotensin system and vascular smooth muscle to control high blood pressure.

- Essential hypertension: lowers systolic and diastolic pressure in patients with primary hypertension. - Isolated systolic hypertension: reduces elevated systolic pressure, especially in older adults. - Hypertension uncontrolled on monotherapy: adds further blood‑pressure reduction when a single agent is insufficient.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain often related to blood‑pressure changes. - Peripheral edema: swelling of ankles or feet due to fluid accumulation. - Flushing: transient redness of the face or neck. - Fatigue: feeling unusually tired or weak. - Palpitations: awareness of heartbeat irregularities.

Serious or Rare Side Effects: - Angioedema: rapid swelling of lips, tongue or throat requiring emergency care. - Severe hypotension: dangerously low blood pressure with fainting risk. - Hepatic dysfunction: abnormal liver enzymes or jaundice. - Myocardial infarction: chest pain indicating possible heart attack. - Allergic reactions: rash, itching or anaphylaxis. - Heart block: abnormal heart rhythm that may need monitoring.

Patients should be evaluated for safety before initiating therapy.

- Blood pressure monitoring: check regularly to avoid excessive lowering. - Renal function assessment: evaluate creatinine and eGFR, especially in patients with kidney disease. - Electrolyte balance: monitor potassium and sodium levels when used with diuretics. - Hepatic impairment: use cautiously in patients with liver disease. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Olmesartan/Amlodipine may interact with several drug classes.

Major Interactions (Avoid): - Aliskiren in diabetic patients: combined use can increase renal risk. - Potassium‑sparing diuretics: may cause hyper‑kalemia. - NSAIDs: can blunt antihypertensive effect. - Strong CYP3A4 inhibitors (e.g., clarithromycin): raise amlodipine concentrations. - Dual ARB therapy: adds no benefit and raises adverse‑event risk.

Moderate Interactions (Monitor Closely):\n- ACE inhibitors: may increase risk of renal impairment and hyper‑kalemia. - Loop diuretics: can enhance hypotensive effect. - Azole antifungals (e.g., ketoconazole): may increase amlodipine levels. - Beta‑blockers: additive blood‑pressure lowering. - Lithium: possible increase in serum lithium concentrations.